HRK and cancer: BH3 profiling with sensitizing peptides that preferentially disrupt BCL-xL interactions (e.g., HRK) functionally confirmed the strong dependence on BCL-xL as a dominant survival factor that maintains mitochondrial integrity even in minimally primed TIS cancer cells.